Biophytis (BPTSY) Competitors $1.94 -0.99 (-33.79%) As of 04/30/2025 10:22 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock BPTSY vs. ADIL, ATNF, KTTA, SONN, DRMA, AEON, CMND, ALZN, LIXT, and KLTOShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Adial Pharmaceuticals (ADIL), 180 Life Sciences (ATNF), Pasithea Therapeutics (KTTA), Sonnet BioTherapeutics (SONN), Dermata Therapeutics (DRMA), AEON Biopharma (AEON), Clearmind Medicine (CMND), Alzamend Neuro (ALZN), Lixte Biotechnology (LIXT), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Adial Pharmaceuticals 180 Life Sciences Pasithea Therapeutics Sonnet BioTherapeutics Dermata Therapeutics AEON Biopharma Clearmind Medicine Alzamend Neuro Lixte Biotechnology Klotho Neurosciences Biophytis (NASDAQ:BPTSY) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Does the media refer more to BPTSY or ADIL? In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Biophytis. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 0 mentions for Biophytis. Adial Pharmaceuticals' average media sentiment score of 1.29 beat Biophytis' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Biophytis Neutral Adial Pharmaceuticals Positive Is BPTSY or ADIL more profitable? Biophytis' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BiophytisN/A N/A N/A Adial Pharmaceuticals N/A -168.25%-148.46% Which has preferable valuation and earnings, BPTSY or ADIL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiophytisN/AN/A-$18.43MN/AN/AAdial PharmaceuticalsN/AN/A-$5.12M-$3.31-0.24 Which has more risk and volatility, BPTSY or ADIL? Biophytis has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Do analysts prefer BPTSY or ADIL? Adial Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 925.64%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Biophytis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community believe in BPTSY or ADIL? Adial Pharmaceuticals received 110 more outperform votes than Biophytis when rated by MarketBeat users. CompanyUnderperformOutperformBiophytisN/AN/AAdial PharmaceuticalsOutperform Votes11058.51% Underperform Votes7841.49% Do institutionals & insiders have more ownership in BPTSY or ADIL? 0.1% of Biophytis shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 5.2% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryAdial Pharmaceuticals beats Biophytis on 11 of the 13 factors compared between the two stocks. Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$681,000.00$6.71B$5.49B$7.95BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3522.6218.58Price / SalesN/A241.98397.85103.49Price / CashN/A65.8538.1834.62Price / Book-0.126.496.744.25Net Income-$18.43M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.24%1.59%1.36%1 Month PerformanceN/A7.16%4.09%3.85%1 Year Performance-78.00%-2.45%15.98%5.37% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$1.94-33.8%N/A-78.7%$681,000.00N/A0.0030Gap DownADILAdial Pharmaceuticals3.4082 of 5 stars$0.71+4.2%$8.00+1,020.4%-59.4%$4.70MN/A-0.2220Short Interest ↓News CoverageGap UpATNF180 Life SciencesN/A$0.89+0.6%N/A-58.6%$4.59MN/A0.007Short Interest ↑News CoverageKTTAPasithea Therapeutics0.5139 of 5 stars$1.69-2.3%N/A-76.0%$4.57MN/A-0.133SONNSonnet BioTherapeutics1.3844 of 5 stars$1.49+8.8%$20.00+1,242.3%-19.2%$4.57M$1M0.0010Short Interest ↑Gap UpDRMADermata Therapeutics2.9276 of 5 stars$0.75+1.8%$6.00+697.9%-82.9%$4.54MN/A-0.058Upcoming EarningsAEONAEON Biopharma1.712 of 5 stars$0.42-2.4%$360.00+85,614.3%-99.8%$4.42MN/A2.335CMNDClearmind Medicine1.0732 of 5 stars$1.03+1.0%N/A-15.0%$4.39MN/A-0.55N/AShort Interest ↓Gap DownALZNAlzamend Neuro3.4961 of 5 stars$0.66-2.6%$20.00+2,921.1%-90.7%$4.38MN/A0.004Short Interest ↓Negative NewsGap UpLIXTLixte Biotechnology1.0895 of 5 stars$1.39+8.2%N/A-56.4%$4.36MN/A-0.804Upcoming EarningsPositive NewsGap UpKLTOKlotho NeurosciencesN/A$0.18+5.0%N/AN/A$4.35MN/A0.00N/AGap Up Related Companies and Tools Related Companies Adial Pharmaceuticals Alternatives 180 Life Sciences Alternatives Pasithea Therapeutics Alternatives Sonnet BioTherapeutics Alternatives Dermata Therapeutics Alternatives AEON Biopharma Alternatives Clearmind Medicine Alternatives Alzamend Neuro Alternatives Lixte Biotechnology Alternatives Klotho Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPTSY Stock Free BPTSY Stock Alerts